Learn about AllerGen’s Michelle Harkness Mentorship Award and nominate someone who is eligible. Check out what’s new in research, participate in two important research studies, and read our latest mythbuster.
Research: Calls for participation
Thank you to those who have already participated in the research studies below. If you have not already participated, please take the time to learn about the studies, and participate before they close.
Please note, researchers are seeking teens to participate in the quality of life study. If you have a teen or know of teens impacted by food allergy, please let them know about this study.
Participate now:
- Teens ages 14-17: Participate in a study that will help to measure quality of life
- Parents: Participate in a survey if your child has had a reaction to an emerging allergen
Call for applications: AllerGen’s Michelle Harkness Mentorship Award – Deadline October 4, 2019
AllerGen NCE Inc. is calling for applications for the Michelle Harkness Mentorship Award, created in honour of the late Michelle Harkness, AllerGen’s Manager of Highly Qualified Personnel (HQP) Training and Events from 2011 to 2017.
If you know someone working in airways and allergic disease whose commitment to mentorship has made a difference in the lives of others, celebrate that person by nominating them for the 2019-2020 Michelle Harkness Mentorship Award. Deadline for submissions is October 4, 2019.
AllerGen NCE Inc. is a national research network dedicated to improving the quality of life of people with allergic and related immune diseases.
Research: DBV submits U.S. application for the Viaskin Peanut patch for children 4-11 years of age
DBV Technologies, a biopharmaceutical company, announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut allergy in children 4-11 years of age.
Viaskin Peanut is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers active peanut proteins to the immune system through the skin.
This submission addresses the additional data needed on manufacturing procedures and quality controls communicated by the FDA in December 2018, when DBV voluntarily withdrew its prior BLA submission for Viaskin Peanut. The FDA had not cited concerns related to the clinical module of the BLA for Viaskin Peanut.
Research: Aimmune enrolls first patient in Phase 2 trial of AR201 for egg allergy
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergy, has announced enrollment of the first patient in its Phase 2 clinical trial on AR201, its investigational oral immunotherapy (OIT) for the treatment of egg allergy.
The study is evaluating the efficacy and safety of AR201 for desensitization in patients four to 26 years of age with hen egg allergy. The trial is expected to enroll about 84 patients at approximately 15 sites in the U.S.
Academic studies of the OIT approach for egg allergy treatment have shown efficacy, and Aimmune is studying this more broadly with AR201 in order to enable widespread availability of a potential treatment.
Mythbuster – Food allergy cannot be outgrown – fact or fiction?
MYTH: Food allergy cannot be outgrown.
FACT: Allergies to peanut, tree nuts, and crustaceans and molluscs tend to be lifelong. Some allergies, such as milk and egg, may be outgrown by school age. Food allergy can start at any age.
Bottom line: Food allergy is serious. It is important to be allergy-aware and learn how to prevent allergic reactions.
Learn more facts on food allergy, tips on preventing allergic reactions, and watch the “Spell it Out” PSA to learn key food allergy information.
Help us educate your communities and share this Mythbuster with them!
Do you have a food allergy myth you would like us to bust? Send your mythbuster questions to info@foodallergycanada.ca.
Tags: advocacy, Research